T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC

Ling Yi,Ziwei Xu,Tianyu Ma,Chong Wang,Panjian Wei,Bo Xiao,Hongtao Zhang,Nanying Che,Zhidong Liu,Yi Han
DOI: https://doi.org/10.1007/s00262-024-03687-5
IF: 6.63
2024-04-16
Cancer Immunology Immunotherapy
Abstract:Neoadjuvant PD-1 blockade combined with chemotherapy is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet the immunological mechanisms contributing to tumor regression and biomarkers corresponding to different pathological responses remain unclear.
oncology,immunology
What problem does this paper attempt to address?